Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
Status:
Recruiting
Trial end date:
2023-07-16
Target enrollment:
Participant gender:
Summary
This trial studies how well leflunomide works for the treatment of patients with CD30+
lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment
(refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.